JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258036

Human LUC7L2 knockout HEK-293T cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

LUC7L2 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
1 Images
Sanger Sequencing - Human LUC7L2 knockout HEK-293T cell lysate (AB258036)
  • Sanger seq

Unknown

Sanger Sequencing - Human LUC7L2 knockout HEK-293T cell lysate (AB258036)

Homozygous : 1 bp insertion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258036-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human LUC7L2 knockout HEK293T cell lysate", "number":"AB258036-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB258036-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
LUC7L2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

LUC7L2 also known as LUC7-like 2 is an RNA-binding protein that plays a role in RNA splicing. It has a molecular mass of approximately 27 kDa. LUC7L2 is expressed in a variety of tissues with a higher expression in the brain and reproductive tissues. It has a specific domain structure that enables it to bind to RNA molecules influencing pre-mRNA processing. The protein is also known to interact with other splicing factors contributing to its function in the cellular nucleus.
Biological function summary

LUC7L2 is an important factor in the regulation of gene expression. It is part of the spliceosome complex which is responsible for the precisely regulated removal of introns from pre-mRNA. This activity impacts the generation of mature mRNA and consequently protein synthesis. LUC7L2 interacts with other components of the spliceosome like the U1 snRNP which ensures accurate and efficient splicing. Through these interactions LUC7L2 helps maintain the fidelity of the splicing process affecting cell function and health.

Pathways

LUC7L2 participates in the mRNA splicing pathway also known as the spliceosome cycle. This protein is involved in both the recognition of splice sites and the catalytic steps of splicing. LUC7L2's activity influences alternative splicing patterns which diversifies the proteome. It interacts with other proteins like the SR proteins which modulate splicing decisions. Its role in the spliceosome cycle highlights its contribution to gene expression regulation.

LUC7L2 has been implicated in neurological disorders and certain cancers. Alterations in LUC7L2 expression or function can lead to aberrant splicing events that disrupt normal cellular activity. In some cancers LUC7L2's interaction with proteins like SF3B1 another spliceosomal component becomes dysregulated contributing to tumorigenesis. Understanding LUC7L2's function and interactions may help develop therapeutic strategies for conditions linked to splicing dysregulation.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com